Microbiome Therapeutics prepares to launch first microbiome modulator after completing Series B financing

261828b1-e8b6-4c71-a5dc-0270aa80590barticleimage.jpg

08 Nov 2017 --- MicroBiome Therapeutics, LLC (MBT), a company that applies the science of the gastrointestinal (GI) microbiome to promote health and wellness, has announced the completion of a Series B financing that raised approximately US$1 million. MBT intends to use the proceeds to launch its clinically-tested microbiome modulator product in 2018.

The dietary supplement is specifically designed to balance and optimize the GI tract and promote healthy metabolism by nourishing and nurturing the growth of healthful gut bacteria, MBT notes. New and existing investors include Lagniappe Angels, NO/LA Angel Network, Zehnder Communications and other private investors.

“We appreciate the support of our investors, which will enable the planned launch of our lead microbiome modulator next year,” says Dale Pfost, Acting CEO of MBT. “This product is a scientific formulation of natural ingredients designed to support a balanced GI microbiome and promote metabolic health in an easy-to-use, flavorful drink mix.”

“Our two clinical trials, conducted at the Pennington Biomedical Research Center and reported in peer-reviewed publications, demonstrated its benefits in helping to manage hunger, maintain healthy blood sugar levels and promote regularity,” Pfost adds.

The product is described as an all-natural blend of prebiotics, including fermentable fiber and polyphenol antioxidants in a patent-pending blend intended to help nurture and nourish beneficial microorganisms in the lower gut.

MBT reports that the launch of its microbiome modulator will be supported by a two-year e-commerce and social media campaign conducted in partnership with New Orleans-based advertising agency Zehnder Communications. MBT is also assembling a nationwide network of registered dietitians and certified diabetic educators to support the launch.

“With MicroBiome Therapeutics, we saw a unique opportunity to apply our product launch expertise in support of an exciting, first-in-class product from a leading science-based company,” says Jeremy Hunnewell, CFO and Business Strategist for Zehnder Communications. “We believe our expertise, along with our integrative and analytical approaches, will enable MBT to inform and educate consumers about this exciting new type of health-promoting dietary supplement.”

“Our investment reinforces our commitment to making a difference by playing a part in the microbiome revolution,” states Hunnewell, who will be joining the board of directors of MBT.

Related Articles

Nutrition & Health News

“Unhelpful”: EU regulatory framework fuels nutrition industry dissatisfaction 

16 Feb 2018 --- A survey reveals that one-third of all nutrition industry professionals believe that the current EU framework for achieving a health claim on new products is stunting innovation because it’s complicated, expensive, long-winded and has several “gray areas.” And “regulation frustration” is a strong feeling running through the industry with many more professionals now believing the current EU regulatory environment is “unhelpful” – a 25 percent hike compared with statistics from the beginning of 2017. Experts are attributing this sharp rise in dissatisfaction to the EU’s tough stance on health claims and the current regulatory deadlock on botanicals.

Nutrition & Health News

Indulgence has reached even America’s healthiest eaters: research

16 Feb 2018 --- New research reveals even the US’ healthiest eaters reach for indulgence foods based on their emotional states. Forty percent of US food-brand lovers who rated their daily diet as extremely healthy agreed with the statement, “When I’m feeling down, I eat something indulgent to make me feel better.” The study, conducted by full-service food branding agency, Foodmix Marketing Communications, breaks out a large group of brand lovers into smaller, differentiated and more actionable consumer segments.  

Nutrition & Health News

Research driving demand for OPO in China’s formula market: Advanced Lipids

16 Feb 2018 --- OPO is increasing in popularity in China’s infant formula market, and according to Advanced Lipids, this is down to the growing body of scientific research backing the benefits of this ingredient. Also known as SN-2 palmitate, OPO is a premium quality ingredient that mimics the fatty acid profile of human milk.

Nutrition & Health News

Vegan diet improves diabetes markers in overweight adults: study

16 Feb 2018 --- A plant-based diet improves beta-cell function and insulin sensitivity in overweight adults with no history of diabetes, according to a new study published in Nutrients by researchers from the Physicians Committee for Responsible Medicine. Measuring the function of beta cells, which store and release insulin, can help assess future type 2 diabetes risk.

Nutrition & Health News

Lactose-free dairy: DSM to market cost-effective analyzer

16 Feb 2018 --- February 2018, DSM will exclusively market BIOMILK 300, a compact residual lactose-analyzing device produced by Biolan. For dairy producers, the BIOMILK 300 is a fast, cost-effective and accurate analyzer for quantifying residual lactose levels in lactose-free and lactose-reduced dairy products.

More Articles
URL : http://www.nutritioninsight.com:80/news/microbiome-therapeutics-prepares-to-launch-first-microbiome-modulator-after-completing-series-b-financing.html